

Presentations by TTUHSC SOM Cancer Center at AACR 2010

Shah ED, Zhao P, Ghent M, Arceci RJ, Buckley J, Reaman G, Triche TJ, Sorensen PHB, Reynolds CP: DrugPath: a web database for academic investigators to identify drugs that match oncology molecular targets Proc Amer Assoc Cancer Res #94, 2010.

Wai DH, Wu DU, Wing MR, Arceci RJ, Reynolds CP, Sorensen PH, Reamon GH, Milos PM, Lawlor ER, Buckley JD, Kapranov PK, Triche TJ: Large intergenic noncoding RNAs associated with Ewing sarcoma family of tumors Proc Amer Assoc Cancer Res #4087, 2010.

Ghent MV, Kim Y, Jakimenko A, Reynolds CP: Resistance to fenretinide in neuroblastoma is associated with increased expression of sphingosine kinase and sphingosine-1-phosphate receptors and targeting sphingosine kinase reverses resistance #5262, 2010.

Houghton PJ, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Smith MA: Pediatric preclinical testing program (PPTP) stage 1 evaluation of BMS-754807 IGF-1 receptor inhibitor #5265, 2010.

Smith MA, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) evaluation of the CDK inhibitor SCH 727965 #5266, 2010.

Potratz J, Saunders D, Wai D, Reynolds CP, Buckley JD, Arceci RJ, Reaman GH, Triche TJ, Jürgens H, Pollak M, Sorensen P HB: Synthetic lethal siRNA screening reveals novel modifiers of insulin-like growth factor-1 receptor (IGF1R) inhibitor activity in childhood sarcomas #3422, 2010.

Cooper JP, Reynolds CP, Curley, RW, Kang MH: Cytotoxicity of fenretinide and its metabolite 4-oxo-4-HPR in malignant lymphoid cells can be dependent and independent of reactive oxygen species (ROS) #1676, 2010.